<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069098/" ref="ordinalpos=2429&amp;ncbi_uid=2883626&amp;link_uid=PMC3069098" image-link="/pmc/articles/PMC3069098/figure/pone-0018373-g005/" class="imagepopup">Figure 5. The effects of Wnt5a on elongation are mediated through Rac1 of the                             non-canonical Wnt/PCP <span class="highlight" style="background-color:">pathway</span>..  From: Wnt5a Regulates Midbrain Dopaminergic Axon Growth and                     Guidance. </a></div><br /><div class="p4l_captionBody">Select antagonists were used to identify the downstream signaling pathway                             responsible for mediating the effects of Wnt5a on DA neurites.                             Antagonism of the canonical Wnt pathway (using Dkk1 recombinant                             protein), the canonical and non-canonical Wnt pathways (using casein                             kinase 1 inhibitor, D4476) and even more selectively the non-canonical                             PCP pathway (using Rac1 inhibitor, NSC23766) revealed that the effect of                             Wnt5a on (<b>A</b>) neurite length and (<b>B</b>) neurite                             number were mediated by the non-canonical PCP pathway (D4476 and                             NSC23766 both significantly antagonizing the effects of Wnt5a).                                 (<b>C</b>–<b>F</b>) Examples of changes in DA                             neuron morphology following treatment with Wnt5a ± selective                             antagonists. Scale bar  = 50 µm. Data                             represents mean ± s.e.m., n = 4–5                             cultures; ** p&lt;0.01, *** p&lt;0.001.</div></div>